🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to researchers.

An International Health Concern

Gonorrhoea infections are on the rise worldwide, with estimates suggesting in excess of 82 million instances per year. Especially elevated rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, the spread of superbugs and the very limited available drugs at this time.”

Public health authorities are deeply concerned about the surge in treatment-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring showed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Gain Authorization

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to major issues, including infertility. Researchers anticipate that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is also used to treat UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Data and Worldwide Availability

Based on data released by a major medical journal, zoliflodacin successfully treated the vast majority of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which combines two antibiotics. The research involved hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Medical professionals directly involved have voiced positive views. Having a one-pill regimen like this is seen as a "critical tool" for gonorrhoea control. This is considered vital to alleviate the strain of the disease for individuals and to prevent the spread of untreatable gonorrhoea globally.